Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial.

ABSTRACT: Recently, tegoprazan was widely used for the treatment of acid-related diseases, including Helicobacter pylori (H. pylori) infection. However, the optimized parameters of tegoprazan and amoxicillin used in dual therapy for eradicating H. pylori remained unresolved. We mainly aim to compare the efficacy and safety of 14-day tegoprazan and low-dose amoxicillin dual therapy (LTA) or high-dose amoxicillin dual therapy (HTA) with 14-day bismuth-containing quadruple therapy (BQT) as first-line treatment of H. pylori infection. The antibiotic resistance and the impacts of therapy on gut microbiota are also evaluated. Study protocol for a multicenter, open-label, non-inferiority, randomized controlled trial. This trial will recruit H. pylori-infected individuals aged 18-70 years without previous e

SUBMITTER: Hu Y 

PROVIDER: S-EPMC12361733 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature